Supernus and Indivior agreed to an all-stock merger of equals to form a new CNS-focused pharma, with the combined company expected to house 11 commercial CNS products. The transaction is structured to be tax-free and is expected to close in the fourth quarter of 2026, with Supernus naming the resulting entity. In radiopharma, Curium entered a definitive agreement to acquire Lantheus Holdings for $102.50 per share at close, with contingent value rights potentially lifting value to as much as $8 billion. Analysts characterized the combination as a manufacturing-and-platform play that could expand geography and broaden theranostics reach. These moves reflect a push to consolidate commercial portfolios and operational capabilities in high-complexity therapeutic areas, including addiction and attention disorders on the CNS side and theranostics/diagnostic distribution in radiopharma.